<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03624296</url>
  </required_header>
  <id_info>
    <org_study_id>2018-35</org_study_id>
    <secondary_id>2018-A00928-47</secondary_id>
    <nct_id>NCT03624296</nct_id>
  </id_info>
  <brief_title>Characterization of Cortical Injury in Early MS Patients: a 7T MRI Study</brief_title>
  <official_title>Characterization of Cortical Injury in Early MS Patients: a 7T MRI Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of the present study is to assess the prevalence, the topography and the&#xD;
      clinical counterpart of cortical lesions in patient included early after the first clinical&#xD;
      episode of multiple sclerosis. A second aim is to assess the direct contribution of cortical&#xD;
      lesions - independent of WM injury - on the diffuse grey matter damage.&#xD;
&#xD;
      Thirty MS patients will be included in the six months after the first clinical episode of&#xD;
      multiple sclerosis for a monocentric transversal MRI study at 7T to assess cortical MS&#xD;
      injury. Clinical (EDSS) and neuropsychological assessments will be performed in the&#xD;
      population the same day of a multi-parametric MRI. MRI protocol is designed to increase the&#xD;
      detection rate of CL using multiple contrasts at high isotropic resolution (600µm3) on a&#xD;
      whole brain exploration. Thus, MRI acquisition will include MP2RAGE, T2*, FLAIR and DIR as&#xD;
      previously published but also recent MRI technique like FLAWS, focusing on the grey matter by&#xD;
      attenuating the white matter and CSF signal. Finally, QSM sequences will be performed. QSM&#xD;
      measures tissue magnetic susceptibility mostly influenced by iron, myelin and calcium content&#xD;
      in the brain. Due to physical properties of the technique (bipolarity), we suppose that high&#xD;
      resolution QSM will be more sensitive that previous used sequences to depict cortical&#xD;
      lesions. Using this multi-contrast approach with relevant MRI sequence and with a high&#xD;
      resolution whole brain exploration might improve the detection of CL in early MS.&#xD;
&#xD;
      Furthermore, MRI protocol allow us to estimate neuronal loss (T1 relaxation time), myelin and&#xD;
      iron content (QSM and T2* relaxation time) within and outside cortical lesions in GM.&#xD;
&#xD;
      The present study is an opportunity to assess cortical pathology in MS from the onset of the&#xD;
      disease, allowing to a better understanding of its origins and its impact and disease&#xD;
      severity. This study is a preliminary requirement to longitudinal studies to precisely depict&#xD;
      the kinetic of cortical lesion accumulation and the links with disease aggravation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">October 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visualization of cortical lesions</measure>
    <time_frame>12 MONTHS</time_frame>
    <description>By IRM 7T</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>measure of physical disability</measure>
    <time_frame>12 months</time_frame>
    <description>score EDSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive impairment index</measure>
    <time_frame>12 months</time_frame>
    <description>score IAC</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Sclerosis (MS)</condition>
  <arm_group>
    <arm_group_label>patient with multiple sclerosis (MS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI 7T</intervention_name>
    <description>MRI 7T</description>
    <arm_group_label>patient with multiple sclerosis (MS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TEST EDSS</intervention_name>
    <description>EDSS - Expanded Disability Status Scale</description>
    <arm_group_label>patient with multiple sclerosis (MS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TEST MSFC</intervention_name>
    <description>MSFC - Multiple Sclerosis Functional Composite</description>
    <arm_group_label>patient with multiple sclerosis (MS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with relapsing-remitting MS (McDonald's criteria 2010) early (duration&#xD;
             evolution &lt;2 years),&#xD;
&#xD;
          -  Age between 18 and 45 years,&#xD;
&#xD;
          -  No history of neurological symptoms suggestive of demyelinating pathology,&#xD;
&#xD;
          -  No corticosteroids in the month preceding the completion of the MRI,&#xD;
&#xD;
          -  Realization of the MRI in the first 6 months following the inaugural clinical episod&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Argument for a differential diagnosis (systemic lupus erythematosus, antiphospholipid&#xD;
             syndrome, Behçet's disease, sarcoidosis, Lyme disease, cerebral arteritis, lymphoma&#xD;
             CNS, etc.),&#xD;
&#xD;
          -  History of neurological or psychiatric illness,&#xD;
&#xD;
          -  History of taking immunosuppressive drugs,&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Pregnancy,&#xD;
&#xD;
          -  Patient unable or unwilling to give consent, patient under guardianship,&#xD;
&#xD;
          -  Patient not affiliated to a social security regime&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jean-olivier ARNAUD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>adil MAAROUF</last_name>
    <email>adil.maarouf@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ALEXANDRA GIULIANI</last_name>
    <phone>+334 91 38 27 47</phone>
    <email>drci@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>alexandra GIULIANI</last_name>
      <phone>04 91 38 27 47</phone>
      <email>drci@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>adil maarouf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>August 6, 2018</last_update_submitted>
  <last_update_submitted_qc>August 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

